The collective voice of early phase COVID-19 vaccine trial participants: Insights for improving confidence in novel vaccines.
Thomas TM. et al, (2023), Human vaccines & immunotherapeutics, 19
Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults
Silk SE. et al, (2023), Med, 4, 668 - 686.e7
Systematic review of the diagnosis and management of necrotising otitis externa: Highlighting the need for high-quality research.
Takata J. et al, (2023), Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 48, 381 - 394
UK consensus definitions for necrotising otitis externa: a Delphi study.
Hodgson SH. et al, (2023), BMJ Open, 13
Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.
Odera DO. et al, (2023), Science translational medicine, 15
Characteristics, management and outcome of a large necrotising otitis externa case series: need for standardised case definition
Hodgson SH. et al, (2022), The Journal of Laryngology & Otology, 136, 604 - 610
Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial.
Hodgson SH. et al, (2022), Clinical and translational science, 15, 524 - 534
Breadth of Antibodies to Plasmodium falciparum Variant Surface Antigens Is Associated With Immunity in a Controlled Human Malaria Infection Study.
Kimingi HW. et al, (2022), Frontiers in immunology, 13
Co-producing Human and Animal Experimental Subjects: Exploring the Views of UK COVID-19 Vaccine Trial Participants on Animal Testing
Vanderslott S. et al, (2021), Science, Technology, & Human Values, 016224392110570 - 016224392110570
Vaccine nationalism and internationalism: perspectives of COVID-19 vaccine trial participants in the United Kingdom
Vanderslott S. et al, (2021), BMJ Global Health, 6, e006305 - e006305
Clinical validation of optimised RT-LAMP for the diagnosis of SARS-CoV-2 infection.
Lim B. et al, (2021), Scientific reports, 11
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116
Development and internal validation of clinical prediction models for outcomes of complicated intra-abdominal infection.
Ahmed S. et al, (2021), The British journal of surgery, 108, 441 - 447
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.
Hodgson SH. et al, (2021), The Lancet. Infectious diseases, 21, e26 - e35
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Voysey M. et al, (2021), The Lancet, 397, 99 - 111
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993